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Alzheimer’s disease (AD) is an age-
related neurodegenerative disorder char-
acterized by global cognitive decline,
with predominant impairments arising
in attention and memory (Perry and
Hodges, 1999). It is the sixth largest
cause of death, and currently there is
no way to prevent, cure, or even slow
the progression (Klafki et al., 2006;
Alzheimer’s Association, 2014). Although
there is a widespread decline in vari-
ous neurotransmitter-containing cell bod-
ies and axonal terminals in AD, the most
consistent losses are seen in the basal
forebrain (BF) cholinergic neurons and
its projections (Mesulam, 2004; Schliebs
and Arendt, 2011). Because of the docu-
mented role of the BF cholinergic system
in learning and memory, the “choliner-
gic hypothesis” of AD was established
(Bartus et al., 1982) and has been the
primary directive for drug development
and treatment in AD for almost three
decades.While cholinomimetic drugs such
as acetylcholinesterase (AChE) inhibitors,
which elevate extracellular levels of the
neurotransmitter acetylcholine (ACh), are
the viable treatment option for AD and
provide moderate alleviation to cogni-
tive impairment, the magnitude of cog-
nitive improvements with these drugs
has remained limited (McGleenon et al.,
1999; Raina et al., 2008). Additionally,
these drugs are not successful in halt-
ing the progression of AD. Furthermore,
the evidence that non-specific block-
ade of either muscarinic or nicotinic
ACh receptors (mAChRs and nAChRs)
alone produce dementia-like symptoms
has remained inconsistent (Little et al.,
1998; Erskine et al., 2004; Roegge and
Levin, 2006). These issues have raised
questions concerning the validity of the
cholinergic hypothesis and whether the
development of procholinergic therapies
as cognition enhancers should be con-
sidered for AD. Here we argue that
psychopharmacological approaches tar-
geting the cholinergic system are based on
previous conceptualizations of ACh regu-
lating arousal states. We urge that emerg-
ing views from recent studies that refine
our understanding of the cholinergic
mediation of specific cognitive processes,
and how cholinergic mechanisms inter-
act with other pathological markers during
the progression of AD, should be consid-
ered while designing procholinergic thera-
pies. This discussion will also focus on the
development of new drug candidates such
as cholinergic receptor subtype-specific
agonists, choline transporter (CHT) mod-
ulators and neurotrophin-based therapeu-
tics to normalize cholinergic function in
AD. Additionally, the need to combine
multiple therapeutic approaches to slow
AD progression and maximize cognitive
benefits will be emphasized.
BF cholinergic neurons located in
the medial septum, vertical and hor-
izontal band of Broca, and nucleus
basalis/substantia innominata complex
innervate the cortical mantle, as well as
the hippocampus. Traditionally, the BF
cholinergic system was described as a dif-
fusely organized neuromodulator system
that influences information processing
throughout the cortex and hippocampus
in the awake brain and during REM sleep
(Woolf, 1991). There are a plethora of neu-
rophysiological studies that demonstrated
that pairing BF stimulation with the stim-
ulation of thalamic afferents enhanced
the processing of sensory inputs, while
the loss of cortical cholinergic inputs or
administration of m/nAChR antagonists
abolished this effect (Sarter et al., 2005).
Additionally, a considerable amount of
evidence generated from psychopharma-
cological and lesion studies indicated that
the BF cholinergic system supports atten-
tional functions, working memory, and
memory consolidation (Furey et al., 2000;
Power et al., 2003; Sarter et al., 2003).
Furthermore, microdialysis studies illus-
trated performance-associated changes in
ACh release in the cortex and hippocam-
pus of rodents performing attention or
memory tasks (Himmelheber et al., 2000;
McIntyre et al., 2002). Together, these data
suggested that the BF cholinergic system
contributes to attention, learning, and
mnemonic processes by generally induc-
ing a state of arousal and elevating sensory
processing by increasing the signal to noise
ratio. Therefore, sustaining extracellular
ACh release by terminating its highly effi-
cient degradation process via AChE was
considered a valid approach to restore
cognitive function in AD.
AChE inhibitors have been in clinical
practice to treat the cognitive symptoma-
tology of mild to moderate AD for almost
two decades. Tacrine was the first approved
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AChE inhibitor for AD. However, due to
a faster half-life and potential to pro-
duce adverse effects, specifically liver tox-
icity, it was replaced by newer AChE
inhibitors such as donepezil, galantamine
and rivastigmine (Knapp et al., 1994;
Ma et al., 2003; Di Santo et al., 2013).
Although AChE inhibitors have been
shown to improve cognitive, specifically
attentional, functions in AD subjects
(Foldi et al., 2005), these improvements
are ultimately inadequate and new pro-
cholinergic approaches are needed (Raina
et al., 2008; Pepeu and Giovannini, 2009).
One possible explanation for limited ther-
apeutic efficacy of AChE inhibitors might
be that besides stimulating the postsy-
naptic cholinergic receptors, higher levels
of baseline ACh levels at the choliner-
gic synapses may also stimulate presy-
naptic autoreceptors, such as muscarinic
M2 receptors, which may shut down the
recruitment of cholinergic inputs during
information processing (Decossas et al.,
2005). Furthermore, the behavioral con-
sequences of sustained postsynaptic m/n
AChR activation remain unknown. The
uncoupling of presynaptic from postsy-
naptic cholinergic signaling is hypothe-
sized to have profound effects on the
neuromodulation of local and efferent
circuitry limiting cognitive enhancement
(Hasselmo and Sarter, 2011).
Advancements in understanding the
multi-temporal modes of cholinergic
transmission offer insight into develop-
ing drug treatments centered on cognition
enhancement. The recent evolution of a
biosensor-based electrochemical approach
formonitoring cholinergic transmission in
real time generated evidence that precisely
orchestrated and temporally restricted
changes in ACh release mediated specific
cognitive operations. In task-performing
animals, phasic (rapid; on a sub-second to
second time scale) increases in choliner-
gic transmission in the prefrontal cortex
mediated the detection of attention-
demanding cues by switching perceptual
processing of the cue to cue-evoked acti-
vation of response rules (Parikh et al.,
2007; Howe et al., 2013). Such transient
increases in behavior-evoked ACh release
were not observed in the motor cortex,
which was used as a neocortical control
region. Moreover, performance-related
tonic (slower; on the time scale ofminutes)
increases in ACh release, which occurred
cortex-wide, fostered and maintained gen-
eral readiness for input processing, and
facilitated signal-driven processes required
for learning and maintaining attention.
The pattern of tonic changes in cholinergic
transmission resembled performance-
related cortical ACh release measured
using microdialysis (Parikh and Sarter,
2008). These temporally-dissociated char-
acteristics of ACh release patterns are also
supported by the electrophysiological evi-
dence demonstrating burst firing and
tonic discharges of BF cholinergic neu-
rons (Unal et al., 2012). Collectively, these
studies led to a major revision of our view
on ACh that was previously considered as
a slowly releasing modulator of arousal
augmenting the gain function of neurons,
to now, as a neurotransmitter that encodes
distinct cognitive operations. This view
emphasizes a need to focus on designing
cholinergic therapies targeting the phasic
component of cholinergic transmission
that is critical for signal detection.
Harnessing this updated view of cholin-
ergic transmission, specific ligands that
activate α4β2 nAChRs may exert procog-
nitive effects by amplifying cholinergic
transients in AD subjects. Cortical cholin-
ergic transients are generated based on
local glutamatergic-cholinergic interac-
tions (Sarter et al., 2009). Stimulus-driven
recruitment of thalamocortical inputs
increases glutamate release, which acti-
vates ionotropic glutamate receptors on
cholinergic terminals and evokes phasic
ACh release. These cholinergic transients
foster detection of signals in attentional
contexts, presumably by producing persis-
tent spiking activity on cortical pyramidal
neurons through postsynaptic mAChRs
(Haj-Dahmane and Andrade, 1998).
Activation of the high-affinity α4β2
nAChRs residing on thalamocortical
afferents also produces phasic increases
in cholinergic activity via similar gluta-
matergic mechanisms (Parikh et al., 2008,
2010). A similar conceptual framework is
applied to septo-hippocampal cholinergic
circuits for encoding of episodic memories
(Hasselmo and Sarter, 2011). Thus, α4β2
nAChRs represent a valid biological target
to develop procognitive drugs that act by
facilitating phasic cholinergic signaling.
Another strategy would be to target
cellular mechanisms that are involved in
ACh production in cholinergic synapses
and are critical to maintaining cholinergic
transmission under conditions of higher
cognitive load. The capacity to import
choline into the presynaptic terminals via
the high-affinity CHTs dictates the rate
of ACh synthesis and release (Ferguson
and Blakely, 2004; Sarter and Parikh,
2005). The mobilization of the intracellu-
lar pools of CHTs to the surface membrane
(CHT trafficking) increases during atten-
tional performance to maintain choliner-
gic transmission (Apparsundaram et al.,
2005). Therefore, aberrations in CHT traf-
ficking may influence phasic ACh release
and attentional functions. In a recent
study, we found that the capacity to gen-
erate cholinergic transients following sus-
tained BF stimulation declined in CHT
heterozygous mice (Parikh et al., 2013b).
Moreover, these mutants displayed atten-
tional impairments and disrupted traffick-
ing of subcellular CHTs. These interesting
results point toward an important role of
CHT function in sustaining phasic cholin-
ergic signaling to maintain cognitive func-
tions. Given the evidence that high-affinity
choline uptake declines in AD (Rodriguez-
Puertas et al., 1994), future research on
developing drugs that activate CHT func-
tion or increase the subcellular trafficking
of CHTs holds promise to be a potential
treatment for restoring cognitive deficits
in AD.
An additional approach to develop-
ing procognitive therapies is targeting
the interaction between BF choliner-
gic neurons, via n/m AChRs, and AD
biomarkers. Among the neuropathological
features of AD, the deposition of fibrillo-
genic β amyloid (Aβ) plaques and accu-
mulation of intracellular neurofibrillary
tangles containing hyperphosphorylated
microtubule-associated protein tau are the
two major hallmarks. Studies involving
transgenic mice harboring mutations in
AD-associated genes including amyloid
precursor protein (APP), presenilin-1 and
tau, have provided insights into possi-
ble reciprocal interactions between cholin-
ergic markers and amyloidosis/tauopathy
(Christensen et al., 2010; Perez et al.,
2011). While it remains debated whether
the cholinergic pathology is the primary
cause or a consequence of AD, efforts
to understand the relationship between
cholinergic signaling and pathological
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substrates of AD are critical to under-
standing the etiology of AD. The interac-
tions between Aβ and α7 nAChRs have
remained complex. For example, the loss
of α7 nAChRs produced cognitive decline
and accumulation of soluble oligomeric
forms of Aβ in 5-month old transgenic
mice harboring the mutation for APP
gene (Hernandez et al., 2010). Conversely,
the activation of α7 nAChR with Aβ was
shown to produce tau phosphorylation
(Hu et al., 2008), and the deletion of this
receptor gene improved memory impair-
ments, reduced gliosis and preserved long-
term potentiation in aged mice modeling
the key pathological features of AD
(Dziewczapolski et al., 2009). These data
present a scenario where α7 nAChR ago-
nists represent a potential strategy for con-
trolling cognitive deficits in early AD that
mostly result from synaptotoxic effects of
Aβ oligomers, while blocking α7 nAChR
function could alleviate cognitive symp-
toms during advanced stages of ADmostly
associated with Aβ plaque and neurofibril-
lary tangles.
There is some evidence that mAChRs
regulate APP processing. Specifically, the
loss of M1mAChRs has been shown
to activate amyloidogenic processing of
APP and greater accumulation of amy-
loid plaques in APP transgenicmice (Davis
et al., 2010). Since M1mAChRs are pre-
dominantly expressed in the cortex and
hippocampus and play a major role in
attention and memory (Soma et al., 2014),
targeting these receptors as a therapeutic
candidate for AD holds promise in com-
pensating for cholinergic hypofunction
while controlling Aβ. Currently efforts to
develop positive allosteric modulators for
M1mAChRs as potential treatment for AD
are ongoing.
Besides the role of Aβ and tau, oxidative
stress and inflammation have also been
considered to account for neurotoxicity
in AD. It is important to note that some
of the modest cognitive benefits of AChE
inhibitors (above) have been actually
ascribed to their anti-inflammatory prop-
erties, which involve inhibition of cytokine
production and antioxidant effects (Chao,
2003; Tabet, 2006). Although a direct link
between central cholinergic mechanisms
and inflammatory processes is still lacking,
more research in this area may provide
new avenues to design procholinergic
therapies for mitigating inflammation
in AD.
The most significant obstacle in bol-
stering cholinergic and cognitive function
in AD is the progressive loss of cholin-
ergic innervation and neurons (Schliebs
and Arendt, 2011). This has spurred drug
discovery efforts to focus on develop-
ing neuroprotective therapies to preserve
cholinergic function in AD. Nerve growth
factor (NGF) is the primary neurotrophic
factor supporting the growth, mainte-
nance, and survival of BF cholinergic
neurons by binding to the high-affinity
tropomyosin-related kinase A (trkA)
receptor (Fagan et al., 1997). Moreover,
activation of p75 NGF receptors is known
to exert detrimental effects on neurons
by triggering apoptotic pathways (Chao,
2003). Postmortem studies have sup-
ported the notion that the loss of trkA
receptors, and presumably the imbal-
ance between trkA and p75 signaling,
contributes to cholinergic dysfunction in
AD (Mufson et al., 2008). We previously
demonstrated that selective reduction of
trkA receptors on BF cholinergic neurons
produces persistent attentional impair-
ments and decline in phasic cholinergic
signaling in aged but not young rats
(Parikh et al., 2013a). Moreover cholin-
ergic dysfunction in trkA-suppressed
aged rats occurred due to age-related
accumulation of proNGF and overacti-
vation of proNGF-p75 signaling (Yegla
and Parikh, 2014). We also found that Aβ
oligomers produced robust impairments
in presynaptic cholinergic signaling and
attentional capacities in aged rats (Parikh
et al., 2014). Because Aβ oligomers are
known to interact with the extracellu-
lar domain of p75 and produce neuritic
degeneration in neuronal culture prepared
from BF cholinergic neurons (Knowles
et al., 2009), oligomeric Aβ-induced dys-
function of cholinergic synapses may be
linked to p75 activation. Collectively, these
findings support the view that interac-
tions between aging/pathological aging
and neurotrophic signaling escalate the
vulnerability of the BF cholinergic system
and neurotrophin-based therapies may
have potential to rescue the loss of this
neurotransmitter system in AD. Therefore,
neuroprotective strategies that provide
trophic support to cholinergic neurons or
that restore trkA/p75 balance may offer
advantage over the current drugs to halt
cognitive deterioration in AD.
Recent research confirms that the era
of developing a “magic bullet” to fos-
ter cognition enhancement in AD is over.
Therefore, we need to consider devising
strategies that focus on a more integrated
or holistic therapeutic approach to pre-
serve cholinergic function and halt cog-
nitive deterioration in AD. In an ideal
scenario, a combination of drugs that aug-
ment phasic cholinergic signaling, block
the interactions between the pathological
markers of AD and the cholinergic pro-
teome, and activate neurotrophic signaling
will maximize cognitive benefits.
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